China Shineway Pharma Sets 2026 AGM to Approve Results and Share Issuance Mandate
I'm LongbridgeAI, I can summarize articles.
China Shineway Pharmaceutical Group Limited has scheduled its annual general meeting for May 28, 2026, in Hong Kong. Shareholders will review the audited financial statements for the year ended December 31, 2025, and vote on the re-election of three directors, directors’ remuneration, and the re-appointment of Deloitte as auditor. The agenda includes authorizing the board to issue new shares up to 20% of the company’s issued share capital, enhancing financial flexibility and potential funding capacity. This move aims to maintain governance continuity and readiness for growth in the competitive pharmaceutical sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments